Page 10 - Dr Reddy's Laboratories
Dr Reddy's Labs extends gains for second straight day, hits 33-month high
Analysts at SBICAP Securities upgraded the stock with 'buy' rating and target price of Rs 3,200 per share
 "Dr Reddy's Labs extends gains for second straight day, hits 33-month high")
Dr Reddy's gives part manufacturing to China partners to tap local market
The products are manufactured either in the plant owned by KRRP in China, or partners in China, or in India by Dr. Reddy's
 "Dr Reddy's gives part manufacturing to China partners to tap local market")
Exposure to US market causing constant FDA scrutiny for big drug firms
Dr Reddy's was in the news for falling short of expectations during routine audits conducted by the US drug regulator
 "Exposure to US market causing constant FDA scrutiny for big drug firms")
Pharma industry needs to develop entire value chain: Dr Reddy's G V Prasad
According to Prasad, the relevance of Indian pharma sector as a provider of affordable alternative to the world remains intact
 "Pharma industry needs to develop entire value chain: Dr Reddy's G V Prasad")
Dr Reddy's enters India's nutrition segment with a drink for diabetics
Dr Reddy's 'Celevida' is formulated to have high protein, high fibre and slowly digested carbohydrates
 "Dr Reddy's enters India's nutrition segment with a drink for diabetics")
Ranitidine recall causes Rs 40-crore dent in Dr Reddy's provisioning
An amount of Rs 17 crore is recognised as a possible refund liability (as a reduction from revenue) arising out of the company's decision to recall the said product
 "Ranitidine recall causes Rs 40-crore dent in Dr Reddy's provisioning")
Dr Reddy's posts 33% rise in profit before tax at Rs 766 crore in Q2
The drug major has reported a 26% increase in revenues at Rs 4,801 crore for Q2
 "Dr Reddy's posts 33% rise in profit before tax at Rs 766 crore in Q2")
Dr Reddy's Q2 net doubles to Rs 1,092 cr on one-off gains, revenues up 26%
Better top-lines numbers come in despite a flattish growth in the firm's US business.
 "Dr Reddy's Q2 net doubles to Rs 1,092 cr on one-off gains, revenues up 26%")
Ranitidine cancer threat: Expect more clarity on products in coming weeks
Ranitidine sales account for 2 per cent of Strides sales and 6 per cent of its profit after tax
 "Ranitidine cancer threat: Expect more clarity on products in coming weeks")
Dr Reddy's gets 4 observations from USFDA for Srikakulam plant
Drug major Dr Reddy's on Saturday said it has received four observations from the US health regulator USFDA for its facility at Srikakulam in Andhra Pradesh. The audit of the company's API Srikakulam Plant (SEZ) by the United States Food and Drug Administration (USFDA) was completed on Friday, the Hyderabad-based pharma major said in a regulatory filing. Dr Reddy's further said that it would address the four concerns within the stipulated timeline. "The audit of our API Srikakulam Plant (SEZ), Andhra Pradesh, by the USFDA, has been completed on October 25, 2019. We have been issued a Form 483 with four observations," said Dr Reddy's. It further said: "We will address them comprehensively within the stipulated timeline." As per the US health regulator, "an FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and ...
China opens public hospitals for Dr Reddy's Laboratories generic drugs
First Indian firm to get contract for supplying generic schizophrenia drug to public hospitals there
 "China opens public hospitals for Dr Reddy's Laboratories generic drugs")
China opens public hospitals for Dr Reddy's Laboratories generic drugs
First Indian firm to get contract for supplying generic schizophrenia drug to public hospitals there
Dr Reddy's Labs shines among pharma stocks, wins investor confidence
The Hyderabad-based company is an outlier among large pharmaceutical producers, having seen a jump in its stock price over the previous year
Dr Reddy's to Lupin, Indian pharma players get a leg up from domestic sales
Dr Reddy's, Lupin, Sun Pharma and Cadila Healthcare outperformed the local industry growth in recent months, a trend expected to continue
 "Dr Reddy's to Lupin, Indian pharma players get a leg up from domestic sales")
Dr Reddy's Labs slumps 8% as US FDA issues CRL for its version of NuvaRing
A CRL is issued when the FDA decides not to approve new or generic drug application for marketing in its present form
PSAI segment decline pulls down Dr Reddy's Q1 show
Earnings were driven by one-off gains
Dr Reddy's Q1 net profit up 45% at Rs 663 cr on rise in generics business
A combination of factors, including an 8% growth in global generics business and the other operating income drove the growth in net profit of Dr Reddy's during the first quarter ended June, 2019
Dr Reddy's Laboratories unveils generic version of Allegra-D in US
Allegra-D 12 HR is a trademark of Aventisub II Inc
Dr Reddy's Q4 net up 44% to Rs 434 cr, annual profit doubles to Rs 1,879 cr
Divestment of derma assets, lower operating costs helped firm post higher profit growth during the quarter
 "Dr Reddy's Q4 net up 44% to Rs 434 cr, annual profit doubles to Rs 1,879 cr")
Dr Reddy's Laboratories renews focus on chronic segment; gets India head
The pharma major is on a restructuring drive